Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.77 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.66 |
| ▸ | IGF1R | P08069 | 3/20 | 0.66 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.60 |
| ▸ | PLCG1 | P19174 | 5/20 | 0.60 |
| ▸ | BTK | Q06187 | 2/20 | 0.59 |
| ▸ | ITK | Q08881 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756300 | 0.91 | DYRK1A (0.72) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3768119 | 0.90 | RIPK1 (0.81) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3763379 | 0.87 | NTRK1 (0.80) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3760839 | 0.87 | NTRK1 (1.00) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3761694 | 0.87 | NTRK1 (0.84) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL17319204 | 0.87 | NTRK1 (0.80) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3771450 | 0.86 | NTRK1 (0.70) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL4167572 | 0.86 | NTRK1 (0.79) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL3768165 | 0.86 | NTRK1 (0.79) | NTRK1KITRIPK1IGF1RTNIK | |
| SCHEMBL17319209 | 0.85 | BTK (0.79) | NTRK1KITRIPK1IGF1RTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| EP-2986300-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2014172513-A2 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | JAK3, ITK, JAK2 | NTRK1 2318/4885KIT 1308/4885RIPK1 22/4885 |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | JAK3, TYK2, JAK2 | NTRK1 1914/4885KIT 1410/4885RIPK1 30/4885 |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | NTRK1 964/4885KIT 1364/4885RIPK1 143/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | NTRK1 997/4885KIT 1240/4885RIPK1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.